FDA approved baxdrostat for adults with hypertension not controlled on other agents, adding a new aldosterone-targeting option.
The FDA has approved
“We have been waiting for an innovative medication like BAXFENDY for hypertension for many years,” Bryan Williams, MD, chair of medicine at University College London and the BaxHTN primary investigator, said in the company announcement. He added that the placebo-adjusted systolic blood pressure reductions seen in phase 3 testing were “clinically meaningful.”1
The approval was based on the
Key Facts
According to the company and the published trial report, mean seated systolic blood pressure fell by 15.7 mm Hg with baxdrostat 2 mg and by 14.5 mm Hg with baxdrostat 1 mg, compared with 5.8 mm Hg with placebo. Placebo-adjusted reductions were 9.8 mm Hg for the 2-mg dose and 8.7 mm Hg for the 1-mg dose, both statistically significant (P < .001). Results were reported to be consistent in both the broader uncontrolled HTN cohort and the resistant HTN subgroup.1,2
Safety will likely shape uptake in practice. The prescribing information summarized in the announcement highlights hyperkalemia and hyponatremia as key warnings, with recommendations for baseline and periodic monitoring of serum potassium and sodium. In pooled placebo-controlled trials, hyperkalemia occurred in 6.6% of patients receiving 1 mg and 10.2% receiving 2 mg; hyponatremia occurred in 2.1% and 3.2%, respectively. Hypotension, dizziness, and muscle spasms were also reported. The recommended dose is 2 mg once daily, with 1 mg advised for patients at increased risk of hyperkalemia or hyponatremia.1
HTN remains the leading modifiable contributor to cardiovascular morbidity and mortality worldwide.3 Contemporary guidelines emphasize combination therapy for many patients and intensified treatment for those with persistent elevation in office or out-of-office readings.3 Yet apparent treatment-resistant HTN remains common, and mineralocorticoid receptor antagonists, while effective, are often limited by adverse effects or tolerability concerns. The clinical rational for Baxdrostat rests on reducing aldosterone synthesis directly through selective inhibition of CYP11B2, the enzyme responsible for aldosterone production.1,4 Earlier clinical work suggests the drug lowers aldosterone without materially affecting cortisol across studied doses, an important consideration for this mechanism.4
The new approval follows a multiyear development program. In a
Even so, several questions remain. The currently available data focus on blood pressure reduction rather than hard cardiovascular or renal outcomes. Longer-term comparative effectiveness against established add-on options, including spironolactone and eplerenone, is not yet defined in the approval materials. Monitoring burden may also prove important in real-world use, particularly among older adults and other individuals with chronic kidney disease, diabetes, or concomitant medications that raise potassium.1
For now, baxdrostat appears positioned as an add-on option for adults whose HTN remains uncontrolled despite other agents. Whether it changes routine care broadly or is used more selectively in persons with suspected aldosterone-driven disease will depend on postmarketing experience, clinician comfort with laboratory monitoring, and future outcomes data.
References
